

Bernardino Alcazar Navarrete

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8309412/publications.pdf>

Version: 2024-02-01

93
papers

1,967
citations

293460

24
h-index

340414

39
g-index

104
all docs

104
docs citations

104
times ranked

2260
citing authors

#	ARTICLE	IF	CITATIONS
1	T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2022, 58, 595-600.	0.4	5
2	ANTES: Un año después en la EPOC. Archivos De Bronconeumologia, 2022, 58, 291-294.	0.4	1
3	Biomarcadores biológicos en las enfermedades respiratorias. Archivos De Bronconeumologia, 2022, 58, 323-333.	0.4	14
4	[Translated article] Biological Biomarkers in Respiratory Diseases. Archivos De Bronconeumologia, 2022, 58, T323-T333.	0.4	11
5	Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir. Drug Design, Development and Therapy, 2022, Volume 16, 827-841.	2.0	12
6	[Translated article] The ANTES Program in COPD: First Year. Archivos De Bronconeumologia, 2022, 58, T291-T294.	0.4	0
7	Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. Archivos De Bronconeumologia, 2021, 57, 13-20.	0.4	46
8	Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study. Archivos De Bronconeumologia, 2021, 57, 122-129.	0.4	21
9	El uso de los espirómetros en el seguimiento de la EPOC: ventajas e inconvenientes. Archivos De Bronconeumologia, 2021, 57, 160-161.	0.4	0
10	El diagnóstico de la EPOC en EPI-SCAN II. Archivos De Bronconeumologia, 2021, 57, 234.	0.4	1
11	Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain. International Journal of COPD, 2021, Volume 16, 2149-2161.	0.9	2
12	Consenso sobre el diagnóstico, tratamiento y seguimiento de la EPOC: Grupo de trabajo EPOC Forum. Archivos De Bronconeumologia, 2021, 57, 596-599.	0.4	2
13	Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. Archivos De Bronconeumologia, 2021, 57, 13-20.	0.4	12
14	Control clínico en la EPOC: ¿un nuevo objetivo terapéutico?. Archivos De Bronconeumologia, 2020, 56, 68-69.	0.4	20
15	Clinical control in COPD: A New therapeutic objective?. Archivos De Bronconeumologia, 2020, 56, 68-69.	0.4	5
16	Small cell lung cancer: Recent changes in clinical presentation and prognosis. Clinical Respiratory Journal, 2020, 14, 222-227.	0.6	3
17	Evaluation of Changes in Control Status in COPD. Chest, 2020, 157, 1138-1146.	0.4	21
18	Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. Archivos De Bronconeumologia, 2020, 56, 651-664.	0.4	20

#	ARTICLE	IF	CITATIONS
19	Management and follow up of respiratory patients in the post-Covid-19 era: Are we ready yet?. Archivos De Bronconeumologia, 2020, 56, 685-686.	0.4	3
20	SARS-CoV-2 Infection in Patients with Lung Cancer: Current Clinical Context. Archivos De Bronconeumologia, 2020, 56, 684.	0.4	0
21	Time for a change: anticipating the diagnosis and treatment of COPD. European Respiratory Journal, 2020, 56, 2002104.	3.1	33
22	<p>A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients</p>. International Journal of COPD, 2020, Volume 15, 1801-1811.	0.9	2
23	<p>Relationship Between Clinical Control, Respiratory Symptoms and Quality of Life for Patients with COPD</p>. International Journal of COPD, 2020, Volume 15, 2683-2693.	0.9	0
24	COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population. Thorax, 2020, 75, 351-353.	2.7	9
25	Implicaciones clínicas del uso de la triple terapia en combinaci3n de dosis fija en EPOC: del ensayo al paciente. Archivos De Bronconeumologia, 2020, 56, 242-248.	0.4	15
26	Predictive value of control of <scp>COPD</scp> for risk of exacerbations: An international, prospective study. Respirology, 2020, 25, 1136-1143.	1.3	24
27	Situaci3n clínic de infecci3n por SARS-CoV-2 en pacientes con carcinoma broncog3nico: contexto actual. Archivos De Bronconeumologia, 2020, 56, 684.	0.4	0
28	The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Archivos De Bronconeumologia, 2020, 56, 242-248.	0.4	11
29	Personalized Medicine in Chronic Obstructive Pulmonary Disease: How Close Are We?. Archivos De Bronconeumologia, 2020, 56, 420-421.	0.4	3
30	Medicina personalizada en la enfermedad pulmonar obstructiva cr3nica: ¿c3mo de cerca estamos?. Archivos De Bronconeumologia, 2020, 56, 420-421.	0.4	8
31	Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers. JMIR Public Health and Surveillance, 2020, 6, e21653.	1.2	13
32	Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care. Archivos De Bronconeumologia, 2019, 55, 478-487.	0.4	11
33	<p>Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study</p>. International Journal of COPD, 2019, Volume 14, 1595-1601.	0.9	11
34	Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. Respiratory Medicine, 2019, 151, 49-54.	1.3	27
35	Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit. PLoS ONE, 2019, 14, e0211732.	1.1	4
36	Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity. Critical Reviews in Oncology/Hematology, 2019, 136, 31-36.	2.0	17

#	ARTICLE	IF	CITATIONS
37	<p>Clinical Features Of Women With COPD: Sex Differences In A Cross-Sectional Study In Spain (â€œThe ESPIRAL-ES Studyâ€).</p>. International Journal of COPD, 2019, Volume 14, 2469-2478.	0.9	16
38	Paciente exacerbador con enfermedad pulmonar obstructiva crÃ³nica: recomendaciones en procesos diagnÃ³sticos, terapÃ©uticos y asistenciales. Archivos De BronconeumologÃ­a, 2019, 55, 478-487.	0.4	16
39	Biopsia lÃ­quida no tumoral: aplicaciÃ³n en neumologÃ­a. Archivos De BronconeumologÃ­a, 2019, 55, 555-556.	0.4	0
40	Anxiety, Depression, and Asthma Control: Changes After Standardized Treatment. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1953-1959.	2.0	77
41	Ã“xido nÃ©trico alveolar y bronquial en la enfermedad pulmonar obstructiva crÃ³nica y el solapamiento de asma y EPOC (ACO). Archivos De BronconeumologÃ­a, 2018, 54, 414-419.	0.4	5
42	Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (GesEPOC): The Epoconsul Study. Archivos De BronconeumologÃ­a, 2018, 54, 270-279.	0.4	11
43	Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respiratory Medicine, 2018, 136, 8-14.	1.3	26
44	AtenciÃ³n mÃ©dica segÃºn el nivel de riesgo y su adecuaciÃ³n a las recomendaciones de la guÃ­a espaÃ±ola de la enfermedad pulmonar obstructiva crÃ³nica (EPOC) (GesEPOC): Estudio EPOCONSUL. Archivos De BronconeumologÃ­a, 2018, 54, 270-279.	0.4	38
45	Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. European Respiratory Journal, 2018, 51, 1701457.	3.1	39
46	The Future of Triple Therapy in Chronic Obstructive Pulmonary Disease. Archivos De BronconeumologÃ­a, 2018, 54, 63-64.	0.4	0
47	Management of COPD in End-of-Life Care by Spanish Pulmonologists. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 171-176.	0.7	21
48	Clinical Guidelines in Asthma and Chronic Obstructive Pulmonary Disease: How Useful Are They in Clinical Practice?. Archivos De BronconeumologÃ­a, 2018, 54, 117-118.	0.4	2
49	Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulmonary Pharmacology and Therapeutics, 2018, 48, 97-103.	1.1	28
50	GuÃ­as clÃ­nicas en asma y enfermedad pulmonar obstructiva crÃ³nica: Â¿cuÃ¡l es su utilidad en la prÃ¡ctica clÃ­nica?. Archivos De BronconeumologÃ­a, 2018, 54, 117-118.	0.4	4
51	Futuro de la triple terapia en la enfermedad pulmonar obstructiva crÃ³nica. Archivos De BronconeumologÃ­a, 2018, 54, 63-64.	0.4	5
52	Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011â€“2016. Journal of Thoracic Disease, 2018, 10, 5468-5475.	0.6	9
53	Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory Research, 2018, 19, 224.	1.4	6
54	Validation of clinical control in COPD as a new tool for optimizing treatment. International Journal of COPD, 2018, Volume 13, 3719-3731.	0.9	39

#	ARTICLE	IF	CITATIONS
55	Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. <i>Pulmonary Therapy</i> , 2018, 4, 171-183.	1.1	12
56	Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: “the ESPIRAL-ES study”. <i>International Journal of COPD</i> , 2018, Volume 13, 1115-1124.	0.9	14
57	Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study. <i>PLoS ONE</i> , 2018, 13, e0198777.	1.1	14
58	Alveolar and Bronchial Nitric Oxide in Chronic Obstructive Pulmonary Disease and Asthma—COPD Overlap. <i>Archivos De Bronconeumologia</i> , 2018, 54, 414-419.	0.4	7
59	Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. <i>International Journal of COPD</i> , 2018, Volume 13, 2279-2288.	0.9	13
60	Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. <i>Advances in Therapy</i> , 2017, 34, 2518-2533.	1.3	79
61	Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 573-580.	0.7	17
62	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , 2017, 53, 574-582.	0.4	0
63	Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada. <i>Archivos De Bronconeumologia</i> , 2017, 53, 574-582.	0.4	2
64	Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 504-512.	0.7	26
65	Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study. <i>Respiratory Research</i> , 2017, 18, 200.	1.4	14
66	Active smoking and COPD phenotype: distribution and impact on prognostic factors. <i>International Journal of COPD</i> , 2017, Volume 12, 1989-1999.	0.9	21
67	A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017, 18, 198.	1.4	38
68	Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. <i>International Journal of COPD</i> , 2017, Volume 12, 417-426.	0.9	50
69	Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate—severe asthma. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000189.	1.2	23
70	Evaluation of symptomatic patients without airflow obstruction: back to the future. <i>Journal of Thoracic Disease</i> , 2016, 8, E1657-E1660.	0.6	4
71	2016 Respiratory Effectiveness Group Annual Summit Report—impact & influence of real-world respiratory evidence. <i>Journal of Thoracic Disease</i> , 2016, 8, S435-S444.	0.6	0
72	The evaluation of a remote support program on quality of life and evolution of disease in COPD patients with frequent exacerbations. <i>BMC Pulmonary Medicine</i> , 2016, 16, 140.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes. Nitric Oxide - Biology and Chemistry, 2016, 54, 67-72.	1.2	31
74	Factors Associated with Depression in COPD: A Multicenter Study. Lung, 2016, 194, 335-343.	1.4	44
75	Validation of the "Test of the Adherence to Inhalers"™ (TAI) for Asthma and COPD Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 142-152.	0.7	146
76	What pulmonologists think about the asthma–COPD overlap syndrome. International Journal of COPD, 2015, 10, 1321.	0.9	35
77	Documento de consenso "Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva cr"nica". Archivos De Bronconeumologia, 2015, 51, 193-198.	0.4	35
78	Xerostomia relates to the degree of asthma control. Journal of Oral Pathology and Medicine, 2015, 44, 273-277.	1.4	9
79	"Correct Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease" A Consensus Document. Archivos De Bronconeumologia, 2015, 51, 193-198.	0.4	19
80	Effect of Inhaled Corticosteroids on Salival Composition: A Cross-Sectional Study in Patients with Bronchial Asthma. Clinical Drug Investigation, 2015, 35, 569-574.	1.1	0
81	The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit. PLoS ONE, 2015, 10, e0134004.	1.1	29
82	The concept of control of COPD in clinical practice. International Journal of COPD, 2014, 9, 1397.	0.9	30
83	Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health and Quality of Life Outcomes, 2014, 12, 120.	1.0	43
84	Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respiratory Medicine, 2014, 108, 737-744.	1.3	34
85	The concept of control in COPD: a new proposal for optimising therapy. European Respiratory Journal, 2014, 44, 1072-1075.	3.1	31
86	Factors Associated With Hospital Admission for Exacerbation of Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2012, 48, 70-76.	0.4	13
87	Repeated Aspergillus isolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection?. BMC Infectious Diseases, 2012, 12, 295.	1.3	18
88	Factors associated with high healthcare resource utilisation among COPD patients. Respiratory Medicine, 2012, 106, 1734-1742.	1.3	41
89	Factores asociados a la hospitalizaci3n por exacerbaci3n de la enfermedad pulmonar obstructiva cr"nica. Archivos De Bronconeumologia, 2012, 48, 70-76.	0.4	26
90	Calcified Pleural Metastasis Secondary to Secondary Hyperparathyroidism. Archivos De Bronconeumologia, 2011, 47, 576.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Neuropsychological Functioning Associated with High-Altitude Exposure. <i>Neuropsychology Review</i> , 2004, 14, 197-224.	2.5	248
92	Hipertensi3n pulmonar tromboemb3lica cr3nica asociada a fibrosis endomioc3rdica del ventr3culo derecho. <i>Archivos De Bronconeumologia</i> , 2003, 39, 370-372.	0.4	6
93	Pulmonologists'™ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey. <i>International Journal of COPD</i> , 0, Volume 17, 1577-1587.	0.9	2